<p>Toxicity information
Oral LDLO (female): 1920 mg/kg/17W (intermittent); Oral LDLO (male): 54 mg/kg/9D (intermittent)<sup class="text-reference-group"><a class="reference-popover-link" data-content="Carbamazepine MSDS" href="#reference-L7156">18</a></sup>
Oral LD50 (rat): 1957 mg/kg <sup class="text-reference-group"><a class="reference-popover-link" data-content="Carbamazepine MSDS" href="#reference-L7156">18</a></sup></p><p>Overdose information</p><p>The initial signs of carbamazepine overdose occur 1-3 hours post ingestion. These signs and symptoms may vary in case of an overdose between carbamazepine and other drugs. Carbamazepine may cause various cardiovascular, neurological, respiratory, urinary symptoms as well as laboratory abnormalities including leukocytosis, reduced leucocytes, acetonuria, and glycosuria.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: EQUETRO (carbamazepine) extended-release capsules" href="#reference-L1335">16</a></sup></p><p>Neuromuscular symptoms may occur initially, followed by mild cardiac symptoms such as tachycardia, hypertension, or hypotension. Higher doses of carbamazepine may cause more severed cardiovascular effects. Restlessness, muscular twitching, tremor, dilated pupils, nystagmus, psychomotor disturbances, and other neurological symptoms may occur. Hyperreflexia in the initial stages of overdose may be followed by hyporeflexia. Nausea, vomiting, urinary retention, dizziness or drowsiness may also occur.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: EQUETRO (carbamazepine) extended-release capsules" href="#reference-L1335">16</a></sup> In cases of overdose, contact the local poison control center. Ensure to provide supportive and symptomatic treatment, which may include monitoring and careful supervision by a medical professional. The possibility of overdose with multiple drugs must be considered in the case of carbamazepine overdose. Maintain an adequate airway, oxygen, in addition to ventilation. Vital signs should be monitored.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: EQUETRO (carbamazepine) extended-release capsules" href="#reference-L1335">16</a></sup></p>